Wilfried Eberhardt
机构: Innere Klinik (Tumorforschung), University of Duisburg-Essen
每年引用次数
引用次数
引用: 37,658
H-指数: 71
I10-指数 : 183
出版物: 711
Phase II Study of 4’-lodo-4’-Deoxydoxorubicin in Patients with Advanced, Measurable Non-Small Cell Lung Cancer
W. Eberhardt , N. Niederle , H. Wilke , B. Weidmann
Onkologie 16 ( 6) 446 -448
1993
Hochdosistherapie und molekulare Therapie beim kleinzelligen Lungenkarzinom
B. Fischer , W. Eberhardt , R. Buhl , M. Thomas
Onkologe 14 ( 8) 798 -805
2008
65P NEOliquid: Detection of KIF5B–RET fusions in liquid biopsy samples
L. Heukamp , R. Menon , J. Müller , S. Lakis
Journal of Thoracic Oncology 11 ( 4) S82 -S83
3
2016
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
P. Christopoulos , W. Engel-Riedel , C. Grohé , C. Kropf-Sanchen
Annals of Oncology 28 ( 8) 1898 -1902
49
2017
Growth patterns of lung metastases from sarcoma: prognostic and surgical implications from histology
S. Welter , F. Grabellus , S. Bauer , M. Schuler
Interactive Cardiovascular and Thoracic Surgery 15 ( 4) 612 -617
11
2012
9015 POSTER DISCUSSION EGFR Mutation Status in NSCLC Patients Stage IIIB/IV in Germany -Initial Results From a German Registry
M. Thomas , W. Eberhardt , J.M. Graf von der Schulenburg , M. Dietel
European Journal of Cancer 47
2011
9144 POSTER EGFR Mutation Testing and First Line Treatment of Patients With Advanced NSCLC and Positive EGFR Mutation Status – Results From a German Registry
W. Eberhardt , M. Thomas , J.M. Graf von der Schulenburg , M. Dietel
European Journal of Cancer 47
4
2011
PP 35 Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer (NSCLC)
D. Christoph , T. Gauler , M. Engelhard , D. Theegarten
European Journal of Cancer 47
2011
Docetaxel als therapeutische Option für die adjuvante Chemotherapie des nicht-kleinzelligen Bronchialkarzinoms
W. Eberhardt
Onkologie 23 ( 6) 22 -24
2
2000
Correlation of p53 genotype and response to induction chemotherapy in advanced non small cell lung cancer (NSCLC)
D. Kandioler , S. Kappel , W. Eberhardt , G. Stamatis
Journal of Clinical Oncology 23 ( 16_suppl) 7043 -7043
2005
Multimodale Therapie des lokal fortgeschrittenen nichtkleinzelligen Bronchialkarzinoms (Stadium IIIa/IIIb)
G. Stamatis , W. Eberhardt , H. Wilke , W. Budach
European Surgery-acta Chirurgica Austriaca 28 ( 2) 82 -85
1996
Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus.
E. Gkika , T. Gauler , W. Eberhardt , M. Stahl
Diseases of The Esophagus 27 ( 7) 678 -684
45
2014
Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer
U. Klaassen , H. Wilke , D. Strumberg , W. Eberhardt
European Journal of Cancer 32 ( 3) 547 -549
64
1996
Übersicht – Therapie des Lungenkarzinoms
W. Eberhardt , M. Hoiczyk , D. Christoph
Tumordiagnostik & Therapie 34 ( 08) 449 -452
2013
Prognostic Value of Metabolic Tumor Volume after Induction Chemotherapy in Stage IIIA/B Non-Small-Cell Lung Cancer – Secondary Analysis of a Randomized Phase 3 Trial
M. Guberina , M. Stuschke , W. Eberhardt , T. Gauler
International Journal of Radiation Oncology Biology Physics 105 ( 1)
2019
Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC
M Lind , S Gettinger , H Borghaei , J Brahmer
Lung Cancer 139
3
2020
2IN EARLY AND LOCALLY ADVANCED DISEASE
W. Eberhardt , S. Senan , W. Weder , C. Faivre-Finn
Lung Cancer 71
1
2011
21IN THE POINT OF VIEW OF THE ONCOLOGIST
W. Eberhardt
Lung Cancer 71
2011
Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation
C. Pöttgen , W. Eberhardt , B. Graupner , D. Theegarten
European Journal of Cancer 49 ( 9) 2107 -2115
18
2013
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Markus Joerger , J Von Pawel , S Kraff , JR Fischer
Annals of Oncology 27 ( 10) 1895 -1902
43
2016
Scott J Antonia Kaid Darwiche Robert pirker Paul Baas kurt werner schmid kenneth o'byrne Marina Chiara Garassino Justin Gainor Naiyer A. Rizvi Nasser Altorki I Vynnychenko Henning Reis, MD Ramón Rami Porta solange peters Fred Hirsch Roy S. Herbst, MD, PhD Leora Horn Heinz Schmidberger Andreas-Claudius Hoffmann Manuel Domine